Theorem Clinical Research

Drug Sponsors

Cipla to expand global footprint, investing in U.K. subsidiary

Wednesday, July 23, 2014 10:42 AM

India-based Cipla has announced a collaboration with the U.K. government to invest up to $170 million in its U.K. subsidiary over the next few years.

More... »


Allergan to restructure, cutting 1,500 employees

Monday, July 21, 2014 03:35 PM

As a result of a review of its operations and processes, Allergan will execute a restructuring it estimates will deliver annual pre-tax savings of approximately $475 million in calendar year 2015. Allergan will focus resources on the highest value opportunities, streamline its organizational structure, simplify processes and interfaces, optimize site footprints and enhancie strategic sourcing of goods and services.

More... »


AstraZeneca reveals designs for new U.K. global R&D center, corporate headquarters

Monday, July 21, 2014 03:03 PM

AstraZeneca revealed its proposed designs for its new global R&D center and corporate headquarters in Cambridge, U.K. The facility, which will be located on the Cambridge Biomedical Campus (CBC), includes the global center, an R&D enabling building and an energy center.

More... »

AbbVie to acquire Shire in $54.6 billion deal

Friday, July 18, 2014 10:24 AM

The boards of AbbVie and Shire have reached agreement on the terms of a recommended combination of Shire with AbbVie that values Shire at approximately $54.61 billion.

More... »

Pfizer to acquire InnoPharma

Thursday, July 17, 2014 12:48 PM

Pfizer has entered an agreement to acquire InnoPharma, a privately held pharmaceutical development company, for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

More... »

Shire willing to discuss AbbVie’s 5th revised proposal

Monday, July 14, 2014 12:48 PM

Following discussions with AbbVie, Shirerequested and has received a further revised proposal from AbbVie on July 13 for a total offering of $53 billion.

More... »

Abbott to sell generics pharmaceuticals business to Mylan, form new entity

Monday, July 14, 2014 12:47 PM

Abbott will sell its non-U.S. developed markets branded generics pharmaceuticals business to Mylan for 105 million shares, or approximately 21%, on a fully diluted basis, of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business. The new entity will be a publicly traded company. This represents a value of approximately $5.3 billion based on Mylan's closing stock price on Friday.

More... »

Prostrakan to acquire Archimedes

Friday, July 11, 2014 11:26 AM

ProStrakan Group, a subsidiary of global specialty pharmaceutical company Kyowa Hakko Kirin (KHK), has entered into an agreement with Novo, a private limited liability company fully owned by the Novo Nordisk Foundation, to purchase the entire share capital of Archimedes Pharma for $394 million in cash.

More... »

Baxter acquires AesRx

Thursday, July 10, 2014 12:51 PM

Baxter International has acquired AesRx, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).

More... »

Salix Pharmaceuticals, Cosmo Technologies to merge

Thursday, July 10, 2014 12:33 PM

Salix Pharmaceuticals will merge with Cosmo Technologies, a subsidiary of Italy-based Cosmo Pharmaceuticals. Salix will become a wholly owned subsidiary of Irish-domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs